Neonates and infants who receive medical care that includes the use of plasticized PVC products may easily be exposed to DEHP at levels that are in excess of the no observed adverse effect level (NOAEL) in animal tests. For some medical therapies, these exposures also exceed the FDA-derived “tolerable intake” (TI).